Background: Activated androgen receptor binds to androgen-responsive elements (AREs) in genome to regulate target gene transcription and, consequently, mediates physiological or tumorigenic processes of the prostate. Our aim was to determine whether genetic variants in AREs are associated with clinical outcomes after androgen-deprivation therapy (ADT) in prostate cancer patients.
effective, ADT eventually fails, leading to prostate cancer progression in a hormone refractory manner [2, 3] .
There are a variety of clinicopathologic parameters, such as tumor stage, Gleason score, and prostate-specific antigen (PSA) kinetics, that have been used in clinical practice to help predict which patients have poor prognoses for disease progression or mortality [4] [5] [6] . However, the clinical parameters' prognostic capabilities are still limited and might be improved by the incorporation of other factors, including genetic markers [7] . Given that the essential role of androgen-AR in prostate cancer and that sequence variants within AREs might affect AR-ARE interaction, resulting in altered target gene expression, we carried out a genome-wide search for the most common genetic variation, single-nucleotide polymorphisms (SNPs), within AREs and investigated their prognostic significance on disease progression, prostate cancer-specific mortality (PCSM), and all-cause mortality (ACM) in a cohort of prostate cancer patients receiving ADT.
patients and methods patient recruitment and data collection
The study population was extended from our hospital-based prostate cancer case-control study, which has been described previously [8] [9] [10] [11] [12] [13] . Briefly, patients with diagnosed and pathologically confirmed prostate cancer were actively recruited from three medical centers in Taiwan: Kaohsiung Medical University Hospital, Kaohsiung Veterans General Hospital, and National Taiwan University Hospital. Prostate cancer patients who had been treated with ADT (orchiectomy or luteinizing hormonereleasing hormone agonist, with or without antiandrogen), including those with disease recurrence after local treatments (radical prostatectomy or radiotherapy), were identified and followed up prospectively to evaluate genetic variants as prognostic predictors of clinical outcomes during ADT. Patients were excluded if the clinicopathologic information or follow-up period was insufficient, leaving 601 patients in this cohort. This study was approved by the Institutional Review Board of the three hospitals, and informed consent was obtained from each participant.
Data were collected on patients with disease baseline and clinicopathologic characteristics, as well as three treatment outcomes: time to progression, PCSM, and ACM. The PSA nadir was defined as the lowest PSA value achieved during ADT treatment [6, 14] . Time to PSA nadir was defined as the length of time it took for the PSA value to reach the nadir after initiation of ADT [4] . Disease progression was defined as a serial rise in PSA, at least two rises in PSA (>1 week apart), reaching values greater than the PSA nadir [15] . Initiation of secondary hormone treatment of rising PSA was also considered as a progression event. Time to progression was defined as the interval in months between the initiation of ADT and progression. In general, patients were followed every month with PSA tests at 3-month intervals. The cause of death was obtained by matching patients' personal identification numbers with the official cause of death registry provided by the Department of Health, Executive Yuan, Taiwan. As presented in Table 1 , 415 (69%) patients exhibited disease progression after ADT, and the median time to progression was 22 months with a mean follow-up of 30.3 months (range, 3-120 months). One hundred and fortyfive (24%) patients died, and 101 (17%) patients died of prostate cancer after a mean follow-up of 39 months (range, 3-125 months). The estimated mean times to PCSM and ACM were 138 and 123 months, respectively. The clinical stage, Gleason score, PSA nadir, time to PSA nadir, and treatment modalities before and during ADT were significantly associated (P £ 0.006) with time to progression, PCSM, and ACM. Age at diagnosis was only associated with ACM, and the PSA level at ADT initiation was associated with time to PCSM and ACM, but it was not associated with time to progression.
SNP selection and genotyping
Since transcription factors have been known to regulate different genes in different cellular contexts [16] , we used PReMod (genomequebec.mcgill.ca/ PReMod), a genome-wide cis-regulatory module prediction database, to identify computationally all putative AREs in the human genome [17] . PReMod used TRANSFAC version 7.2 position weight matrices (PWMs) to score putative transcription factor-binding sites based on how faithfully the binding site in human and its orthologs in mouse and rat match the PWM. In addition, the prediction algorithm of PReMod exploits the observation that many known cis-regulatory modules often contain clusters of phylogenetically conserved and repeated transcription factors' binding sites [18] and thus has proven to be more reliable than other algorithms. The PReMod algorithm predicts that a total of 6590 sites within the human genome are bound by the AR (canonical AR PWM: M00481; consensus: GGTACANNRTGTTCT) [19] . We identified SNPs within AREs by comparing two hexameric half-sites of these putative AREs with HapMap SNPs CHB (Han Chinese in Beijing, China) data in the UCSC table browser (NCBI35/hg17) [20, 21] . SNPs with a minor allele frequency <10% in the HapMap CHB population were excluded, thus leaving 59 SNPs in AREs were initially selected for analysis.
Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) and stored at 280°C until the time of study. Genotyping was carried out as described previously [11] using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry technology at the National Genotyping Center, Academia Sinica, Taiwan. The average genotype call rate for these SNPs was 99.4%, and the average concordance rate was 99.8% among 54 blind duplicated quality control samples. Any SNP that did not conform to the Hardy-Weinberg equilibrium (P < 0.005), or fell below a genotyping call rate of 90%, was removed (N = 4). Thus, a total of 55 SNPs were selected for further statistical analysis.
statistical analysis
Patients' clinicopathologic characteristics were summarized as the number and percentage of patients or the median and interquartile range of values. The continuous factors were dichotomized at the median value within the cohort, with the exception of the PSA nadir, which was dichotomized at 0.2 ng/ml because of its correlation with disease progression and PCSM [5, 6] . The heterozygous and rare homozygous genotypes were collapsed in the analysis if the frequency of the rare homozygote was low (<3%) or if the homozygous and heterozygous genotypes had the same direction of effect. The associations of 55 individual SNPs and clinicopathologic characteristics with time to progression, PCSM, and ACM were assessed using the Kaplan-Meier analysis with log-rank test. Multivariate analyses to determine the interdependency of genotypes and other known prognostic factors, such as age at diagnosis, clinical stage, Gleason score, PSA at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality, were carried out using the Cox proportional hazards regression model. Based on our study population (N = 601), we were able to detect a hazard ratio of 1.6, for a minor allele frequency of 0.2, with over 0.8 statistical power for disease progression, PCSM, and ACM. As we were testing 55 SNPs, falsediscovery rates (q values) were calculated to determine the degree to which the tests for association were prone to false positives [22] . The q value estimates the proportion of results declared interesting (i.e. significant at the nominal P value of 0.05) that is actually false. For example, we carried out 55 statistical tests to assess the associations between SNPs and PCSM with an a of 0.05 and then about three tests on average would produce P <0.05 by chance alone. Five SNPs were associated with PCSM with nominal P <0.05 and all had q £0.108, indicating that of all the results declared interesting (five SNPs), 10.8% of these were likely to be false (less than one false positive). No thresholds for the selection of a particular q value have been established in candidate gene investigations. However, it has been suggested that a threshold <0.20 would be considered reasonable [23] . The q values were estimated using R q value package (http://genomics.princeton.edu/ storeylab/qvalue/) to analyze the observed distribution of P values from the log-rank test for 55 SNPs. The Statistical Package for the Social Sciences software version 16.0.1 (SPSS Inc., Chicago, IL) was used for other statistical analyses. A two-sided P value of <0.05 was considered statistically significant.
results
Univariate log-rank tests of the 55 SNPs in AREs regarding time to progression, PCSM, and ACM after ADT were summarized in supplemental Table 1 , available at Annals of Oncology online. In the first analysis, ACTN2 rs4659711 and NR2F1 rs10074743 original articles Annals of Oncology were associated with disease progression (nominal P £ 0.044), and all had a false-discovery rate (q value) of £0.562 (Table 2) . Five SNPs were associated with PCSM with nominal P £0.025 and q £0.108 (ARRDC3 rs2939244, XRCC6BP1 rs12824706, FLT1 rs9508016, PSMD7 rs328318, and SKAP1 rs6504145; Table 3 ). Four SNPs, FBXO32 rs7830622, XRCC6BP1 rs12824706, FLT1 rs9508016, and FLRT3 rs4140562, exhibited significant effects on ACM (nominal P £ 0.038), and all had a q value of £0.243 (Table 4) .
To assess the predictive effects of these SNPs beyond the clinical features to influence outcomes after ADT, we carried out a multivariate analysis, adjusting for age at diagnosis, clinical stage, Gleason score, PSA level at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality. After adjusting for these predictors, no statistical association was observed between any SNPs and disease progression (P > 0.050; Table 2 ). However, three (ARRDC3 rs2939244, FLT1 rs9508016, and SKAP1 rs6504145) and two (FBXO32 rs7830622 and FLT1 rs9508016) polymorphisms remained as significant predictors for time to PCSM and ACM, respectively (P £ 0.035; Tables 3 and 4) .
A gene-dosage effect on PCSM and ACM was found when three genetic loci of interest related to PCSM and two genetic loci of interest associated with ACM were analyzed in combination (log-rank P < 0.001, Tables 3 and 4 and Figure 1 , left). The time to PCSM and ACM decreased as the number of Column subtotals do not sum to 601 for number of patients due to missing data. b P values were calculated using the log-rank test.
ADT, androgen-deprivation therapy; PCSM, prostate cancer-specific mortality; ACM, all-cause mortality; PSA, prostate-specific antigen; IQR, interquartile range.
unfavorable genotypes increased, and the combined genotype remained as a significant predictor after adjusting for other clinical factors (P for trend < 0.001, Tables 3 and 4) . To further evaluate the clinical relevance of these SNPs in AREs, we risk-stratified patients with respect to their metastatic status at the initiation of ADT. The combined genotypes still had significant effects on PCSM in patients with or without distant metastases (P £ 0.019, Figure 1A , middle and right). This additional information further supports an enhancement of risk prediction for PCSM in both low-and high-risk patients, whereas the incorporation of combined genotypes only leads to better risk prediction for ACM in the high-risk patients with distant metastases (P < 0.001, Figure 1B, right) , not in patients without metastases (P = 0.253, Figure 1B , middle).
discussion
It has been well documented that AR mediates essential processes in normal and cancerous prostate development and still persists in the majority of patients with hormone refractory disease [24] [25] [26] . The classical activation mechanism of AR involves the binding of androgen and other coregulators to form the androgen-AR complex, which binds to AREs in the promoter regions of androgen target genes, regulating their transcription and consequently mediating androgen's physiological or tumorigenic effects. Thus, sequence variants within AREs might affect AR-ARE interactions, and it is meaningful to assess the associations between common genetic variants in AREs and prostate cancer progression. The SNPs we genotyped were based on genome-wide-predicted AREs and, ADT, androgen-deprivation therapy; SNP, single-nucleotide polymorphism; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen. ACM, all-cause mortality; ADT, androgen-deprivation therapy; SNP, single-nucleotide polymorphism; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen. 
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therefore, provided a unique opportunity to examine comprehensively putative AREs without depending on a prior hypothesis. Our study took advantage of these hybrid designs of candidate androgen-responsive genes and genome-wide approaches. Furthermore, this study is one of the largest carried out in advanced prostate cancer for which ADT was the main therapeutic intervention. We found that 4 of 55 SNPs in AREs were significantly associated with PCSM or ACM in prostate cancer patients receiving ADT, remaining so in multivariate analyses after controlling for other known clinicopathologic risk factors (age, clinical stage, Gleason score, PSA level at ADT initiation, PSA nadir, time to PSA nadir, and treatment modality). Moreover, strong combined genotype effects on PCSM and ACM were also observed. To our knowledge, no previous studies have investigated these associations.
Of the 55 SNPs evaluated, ARRDC3 rs2939244, FLT1 rs9508016, SKAP1 rs6504145, and FBXO32 rs7830622 exhibited significant associations with PCSM or ACM after adjusting for all clinical predictors. Of these, FLT1 rs9508016 was significantly associated with both PCSM and ACM during ADT. The closest known gene to rs2939244 is the arrestin domain-containing 3 (ARRDC3) gene. Although rs2939244 is located 395-kb upstream of ARRDC3, rs2939244 could still regulate ARRDC3 expression through enhancers, which have been demonstrated to be able to regulate target genes from >1 Mb away. ARRDC3 has been classified as an a-arrestin, which contains structural homology to the arrestin family, suggesting a role in the internalization and regulation of membrane proteins [27] . A recent study has found that ARRDC3 is preferentially lost in some breast cancers, and overexpression of ARRDC3 repressed cancer cell proliferation, migration, invasion, and in vivo tumorigenicity through the degradation of a cell surface adhesion molecule, b-4 integrin, associated with aggressive tumor behavior [28] . ARRDC3 was up-regulated in the muscle cells of male AR knockout mice [29] , implying that androgens might negatively regulate ARRDC3 expression and increase the risk of aggressive prostate cancer. rs9508016 is intronic to FLT1, fms-related tyrosine kinase 1, which encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. Vascular endothelial growth factor (VEGF) is vital to physiological and pathological angiogenesis, largely by activating its receptors, FLT1 and kinase insert domain receptor (KDR). Most biological functions of VEGF are mediated via KDR, whereas the role of FLT1 remains to be clarified. Recently, the expression of FLT1 has been correlated with a higher Gleason grade, pathological stage, and microvessel density in the premalignant and malignant tissues when compared with normal prostatic glands [30] . Consistent with the prediction of ARE in FLT1, a dose-dependent increase in the expression of FLT1 by androgen treatment implies that FLT1 might be an androgen target gene [31] . Several small molecule inhibitors targeting VEGFRs have been shown to exhibit some activity in prostate cancer, suggesting that the use of antiangiogenesis agents in prostate cancer might be promising [32, 33] . rs6504145 is an intronic SNP in src kinaseassociated phosphoprotein 1 (SKAP1) that has strong homology to the src oncogene at the C-terminal end. SKAP1 was shown to be involved in the regulation of the Ras oncogenic pathway and mitotic progression, specifically at the metaphase-to-anaphase transition [34, 35] . A genome-wide association study also identified an ovarian cancer susceptibility locus in SKAP1 [36] . rs7830622 is located in the intron of the Fbox protein 32 (FBXO32) gene, which encodes a member of the F-box protein family and constitutes a subunit of the phosphorylation-dependent ubiquitin protein ligase complex [37] . FBXO32 was originally reported to be involved in muscle atrophy, but recent findings suggest that FBXO32 is a novel apoptosis regulator [38] . FBXO32 was downregulated in some ovarian cancer cell lines, and restoration of FBXO32 sensitized platinum-resistant ovarian cancer cells to cisplatin by upregulating apoptosis. Furthermore, ovarian cancer patients with high FBXO32 methylation levels exhibited significantly shorter progression-free survival times than did those with low methylation levels [39] . The expression level of FBXO32 was decreased in mice after orchidectomization, and its expression could be restored by both estrogen and androgen treatments of orchidectomized mice [40] , indicating that FBXO32 might be an androgen-regulated gene.
Taken together, using a genome-wide approach to study the common variants in AREs, our research reveals multiple unappreciated pathways affecting survival after ADT, such as ARRDC3 in membrane receptor desensitization, FLT1 in angiogenesis, SKAP1 in cell cycle regulation, and FBXO32 in apoptosis. The genetic variants identified in this study might not only encourage further investigation of the implicated signaling pathways on ADT but also produce clinically useful biomarkers. However, the current findings are hypothesis generating, and the results reported here are limited by analyzing the small number of patients in a genetic subset and multiple comparisons. In addition, our homogeneous Chinese Han population might make our findings less applicable to other ethnic groups. Larger studies in the future are warranted to confirm our findings in other ethnical cohorts, and more thorough functional analyses will clarify the role of these SNPs/genes in the course of prostate cancer progression.
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